Skyramp | $10,000,000 | (Jun 25, 2025)
Claira(US) | $7,000,000 | (Jun 25, 2025)
Eventual | $20,000,000 | (Jun 25, 2025)
Certified by Founder
Lodge
ProJenX
start up
United States
- New York, NY
- 03/11/2023
- Series A
- $15,000,000
ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.
- Industry Biotechnology Research
- Website https://projenx.com/
- LinkedIn https://www.linkedin.com/company/projenx-inc/about/
CubeNexus Inc | $650,000 | (Jun 25, 2025)
Digital Asset | $135,000,000 | (Jun 25, 2025)
Quinn | $11,000,000 | (Jun 25, 2025)
Waltz | $50,000,000 | (Jun 25, 2025)
OutSee | $2,452,266 | (Jun 25, 2025)
Jobright.ai | $3,200,000 | (Jun 25, 2025)
Empo Health | $7,000,000 | (Jun 25, 2025)
Blank Metal | $3,000,000 | (Jun 25, 2025)
Chronicle Studios | $11,000,000 | (Jun 25, 2025)
Gemist | $6,000,000 | (Jun 25, 2025)